Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-29T12:45:37.627Z Has data issue: false hasContentIssue false

19 - Integrating Cognitive Behavioral Therapy and Medications for the Treatment of Obsessive-Compulsive Disorder

from Section 2 - Practical Aspects of Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  14 December 2018

Leonardo F. Fontenelle
Affiliation:
Federal University of Rio de Janeiro
Murat Yücel
Affiliation:
Monash University, Victoria
Get access
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ruscio, AM, Stein, DJ, Chiu, WT, Kessler, RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):5363.Google Scholar
Foa, EB, Liebowitz, MR, Kozak, MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151161.Google Scholar
Simpson, HB, Foa, EB, Liebowitz, MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70(11):11901199.Google Scholar
Simpson, HB, Huppert, JD, Petkova, E, Foa, EB, Liebowitz, MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269276.Google Scholar
Marks, IM, Lelliott, P, Basoglu, M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry. 1988;152(4):522534.Google Scholar
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):5662.Google Scholar
Cottraux, J, Mollard, E, Bouvard, M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1990;5(1):1730.CrossRefGoogle ScholarPubMed
Hohagen, F, Winkelmann, G, Rasche-Räuchle, H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry. 1998;(35):7178.CrossRefGoogle ScholarPubMed
Goodman, WK, Price, LH, Rasmussen, SA, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):10061011.Google Scholar
Goodman, WK, Price, LH, Rasmussen, SA, et al. The yale-brown obsessive compulsive scale: II. Validity. Arch Gen Psychiatry. 1989;46(11):10121016.Google Scholar
Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292(16):19691976.Google Scholar
Scahill, L, Riddle, MA, McSwiggin-Hardin, M, et al. Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844852.Google Scholar
Simpson, HB, Maher, MJ, Wang, Y, Bao, Y, Foa, EB, Franklin, M. Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder. J Consult Clin Psychol. 2011;79(2):247.CrossRefGoogle ScholarPubMed
Wheaton, MG, Galfalvy, H, Steinman, SA, Wall, MM, Foa, EB, Simpson, HB. Patient adherence and treatment outcome with exposure and response prevention for OCD: which components of adherence matter and who becomes well? Behav Res Ther. 2016;85:612.Google Scholar
Cottraux, J, Mollard, E, Bouvard, M, Marks, I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res. 1993;49(1):6375.CrossRefGoogle ScholarPubMed
Simpson, HB, Liebowitz, MR, Foa, EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive–compulsive disorder. Depress Anxiety. 2004;19(4):225233.Google Scholar
Patel, SR, Galfavy, H, Kimeldorf, MB, Dixon, LB, Simpson, HB. Patient preferences and acceptability of evidence-based and novel treatments for obsessive-compulsive disorder. Psychiatric Serv. 2017;68(3):250257.Google Scholar
Patel, SR, Simpson, HB. Patient preferences for OCD treatment. J Clin Psychiatry. 2010;71(11):1434.Google Scholar
Koran, LM, Hanna, GL, Hollander, E, Nestadt, G, Simpson, HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7):1.Google ScholarPubMed
Koran, LM, Simpson, HB. Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Washington, DC: American Psychiatric Association; 2013.Google Scholar
Marks, IM, Stern, RS, Mawson, D, Cobb, J, McDonald, R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry. 1980;136(1):125.Google Scholar
Van Balkom, AJ, De Haan, E, Van Oppen, P, Spinhoven, P, Hoogduin, KA, Van, Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186(8):492499.Google Scholar
Tenneij, NH, Van, Megen HJ, Denys, DA, Westenberg, HG. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry. 2005;66(9):11691175.Google Scholar
Simpson, HB, Foa, EB, Liebowitz, MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621630.CrossRefGoogle ScholarPubMed
Simpson, HB, Foa, EB, Liebowitz, MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70(11):11901199.Google Scholar
Bloch, M, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, MB, Leckman, JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622632.CrossRefGoogle ScholarPubMed
Komossa, K, Depping, AM, Meyer, M, Kissling, W, Leucht, S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;(12):CD008141.Google Scholar
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557574.Google Scholar
Veale, D, Miles, S, Smallcombe, N, Ghezai, H, Goldacre, B, Hodsoll, J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):317.Google Scholar
Foa, EB, Simpson, HB, Rosenfield, D, et al. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and ritual prevention or risperidone in adults with obsessive-compulsive disorder. J Clin Psychiatry. 2015;76(4):440.CrossRefGoogle ScholarPubMed
Franklin, ME, Sapyta, J, Freeman, JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011;306(11):12241232.CrossRefGoogle ScholarPubMed
New York State Psychiatric Institute. Attaining and maintaining wellness in obsessive-compulsive disorder. ClinicalTrials.gov Identifier NCT01686087. Available from: https://clinicaltrials.gov/ct2/show/NCT01686087 (accessed July 26, 2018).Google Scholar
Fanale, MA, Horwitz, SM, Forero-Torres, A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):31373143.Google Scholar
Kalanthroff, E, Anholt, GE, Simpson, HB. Research domain criteria and obsessive-compulsive disorder: an oxymoron? In: Pittenger, C, ed. Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. New York, NY: Oxford University Press; 2017:609702.Google Scholar
Ledgerwood, L, Richardson, R, Cranney, J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117(2):341.Google Scholar
Walker, DL, Ressler, KJ, Lu, KT, Davis, M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):23432351.Google Scholar
Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):11361144.Google Scholar
Tart, CD, Handelsman, PR, DeBoer, LB, et al. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013;47(2):168174.Google Scholar
Nave, AM, Tolin, DF, Stevens, MC. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry. 2012;73(9):11791186.Google Scholar
Otto, MW, Tolin, DF, Simon, NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010;67(4):365370.Google Scholar
Siegmund, A, Golfels, F, Finck, C, et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011;45(8):10421047.CrossRefGoogle ScholarPubMed
Hofmann, SG, Meuret, AE, Smits, JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298304.Google Scholar
Guastella, AJ, Richardson, R, Lovibond, PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63(6):544549.Google Scholar
Hofmann, SG, Smits, JA, Rosenfield, D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170(7):751758.Google Scholar
Sheerin, CM. Slope of Change through D-cycloserine Facilitation of Exposure Therapy in a Social Anxiety Population. Dissertation, Western Michigan University; 2013.Google Scholar
Kushner, MG, Kim, SW, Donahue, C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835838.Google Scholar
Wilhelm, S, Buhlmann, U, Tolin, DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335341.Google Scholar
Storch, EA, Merlo, LJ, Bengtson, M, et al. D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder. Int Clin Psychopharmacol. 2007;22(4):230237.Google Scholar
Andersson, E, Hedman, E, Enander, J, et al. D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):659667.CrossRefGoogle ScholarPubMed
Farrell, LJ, Waters, AM, Boschen, MJ, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety. 2013;30(8):723731.Google Scholar
Mataix-Cols, D, Turner, C, Monzani, B, et al. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry. 2014;204(1):7778.Google Scholar
Storch, EA, Wilhelm, S, Sprich, S, et al. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted D-cycloserine vs placebo in pediatric obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(8):779788.Google Scholar
Mataix-Cols, D, de la Cruz, LF, Monzani, B, et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017;74(5):501510.Google Scholar
Pittenger, C, Krystal, JH, Coric, V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):6981.Google Scholar
Carlsson, ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(1):526.Google Scholar
Chakrabarty, K, Bhattacharyya, S, Christopher, R, Khanna, S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):17351740.Google Scholar
Rosenberg, DR, Hanna, GL. Genetic and imaging strategies in obsessive–compulsive disorder: potential implications for treatment development. Biol Psychiatry. 2000;48(12):12101222.Google Scholar
Rosenberg, DR, MacMaster, FP, Keshavan, MS, Fitzgerald, KD, Stewart, CM, Moore, GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):10961103.Google Scholar
Ting, JT, Feng, G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008;2:6271.CrossRefGoogle ScholarPubMed
Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351354.Google Scholar
Kishimoto, T, Chawla, JM, Hagi, K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(07):14591472.Google Scholar
Gideons, ES, Kavalali, ET, Monteggia, LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA. 2014;111(23):86498654.Google Scholar
Liu, RJ, Lee, FS, Li, XY, Bambico, F, Duman, RS, Aghajanian, GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012 Jun 1;71(11):9961005.CrossRefGoogle ScholarPubMed
Craske, MG, Treanor, M, Conway, CC, Zbozinek, T, Vervliet, B. Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:1023.Google Scholar
Rodriguez, CI, Kegeles, LS, Levinson, A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):24752483.Google Scholar
Rodriguez, CI, Wheaton, M, Zwerling, J, et al. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J Clin Psychiatry. 2016;77(3):408.Google Scholar
Fitzgerald, PJ, Seemann, JR, Maren, S. Can fear extinction be enhanced? A review of pharmacological and behavioral findings. Brain Res Bull. 2014;105:4660.Google Scholar
Nader, K, Hardt, O. A single standard for memory: the case for reconsolidation. Nat Rev Neurosci. 2009;10(3):224234.Google Scholar
Nader, K, Schafe, GE, Le Doux, JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406(6797):722726.Google Scholar
Tronson, NC, Taylor, JR. Molecular mechanisms of memory reconsolidation. Nat Rev Neurosci. 2007;8(4):262275.Google Scholar
Soeter, M, Kindt, M. Disrupting reconsolidation: pharmacological and behavioral manipulations. Learn Mem. 2011;18(6):357366.Google Scholar
Kindt, M, Soeter, M, Vervliet, B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12(3):256.Google Scholar
Soeter, M, Kindt, M. An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry. 2015;78(12):880886.Google Scholar
Brunet, A, Orr, SP, Tremblay, J, Robertson, K, Nader, K, Pitman, RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42(6):503506.Google Scholar
Shiban, Y, Pauli, P, Mühlberger, A. Effect of multiple context exposure on renewal in spider phobia. Behav Res Ther. 2013;51(2):6874.Google Scholar
Vansteenwegen, D, Vervliet, B, Iberico, C, Baeyens, F, Van den, Bergh O, Hermans, D. The repeated confrontation with videotapes of spiders in multiple contexts attenuates renewal of fear in spider-anxious students. Behav Res Ther. 2007;45(6):11691179.Google Scholar
Balooch, SB, Neumann, DL, Boschen, MJ. Extinction treatment in multiple contexts attenuates ABC renewal in humans. Behav Res Ther. 2012;50(10):604609.Google Scholar
Dunsmoor, JE, Campese, VD, Ceceli, AO, LeDoux, JE, Phelps, EA. Novelty-facilitated extinction: providing a novel outcome in place of an expected threat diminishes recovery of defensive responses. Biol Psychiatry. 2015;78(3):203209.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×